Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
February 07, 2019 09:18 ET | Source: Vystar Corp
RX3000 Germicidal UV Light Air Purifier for Hospitals
The Rx3000 UV light air purification system for hospitals, which has been proven in laboratory tests to inactivate airborne pathogens, will be available in the second quarter of 2019 via Vystar’s medical distribution network.
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.
Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other antibiotic-resistant and viral infections.
WORCESTER, Mass., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Vystar Corp. (OTC: VYST) is resuming production of the Rx3000™, a hybrid air purifier designed by biomedical engineers specifically for hospitals. The Rx3000 combines powerful germicidal ultraviolet (UV) light with a patented 5-stage HEPA filtration proven in independent EPA- and FDA-certified laboratory testing to destroy on first pass over 99.97% of airborne viruses, bacteria and other contaminants. Vystar acquired the assets and patented intellectual property related to the Rx3000, RxAir™, custom filtration and other UV light air purification technologies from UV Flu Technologies in 2018 after production had stopped.
Rx3000 is used in over 400 hospitals and is FDA-cleared as a Class II Medical Device. Priced at less than $5,000 per unit to service a 1,500 – 3,000 sq. ft. area, Rx3000 is very cost effective. Vystar also acquired all of the equipment necessary to make the custom filters used in the Rx3000. These large multi-stage filters retail for approximately $800 and last up to 1 year, depending on use. Vystar expects the first new Rx3000 units will be available to hospitals in the second quarter of 2019 via Vystar’s medical distribution network partners.
“Measles, influenza, strep, MRSA (staph), pneumonia, tuberculosis and other airborne illnesses are a major concern for hospitals and healthcare facilities year round,” stated Bryan Stone, MD, Internal Medicine and Nephrology, Chief of Medicine for Desert Regional Medical Center, and expert consultant for medical application and technology development. “We believe it is important that hospitals have access to the Rx3000 technology that helps reduce risk of infection from airborne antibiotic-resistant viruses and bacteria. We also encourage consumers to stay up to date on their vaccinations and follow good hygiene practices by frequently washing their hands with soap and water.”
Dr. Stone noted, “No matter how much you sanitize a room’s surfaces, it is all undone by the simple act of an infected person exhaling, sneezing or coughing harmful viruses or bacteria that can be inhaled and infect non-immune individuals. The CDC states that ‘Measles is so contagious that if one person has it, 90% of the people close to that person who are not immune will also become infected. Infected people can spread measles to others from four days before through four days after the rash appears. The Rx3000 very efficiently inactivates airborne pathogens to reduce risk of infection.”
Additional Rx3000 features include:
Patented 5-stage HEPA filtration design
Germicidal ultraviolet irradiation system
Virtually maintenance-free, with ultra quiet design
Operator-friendly controls with easy portability
HEPA and pre-filter changes in seconds
In previous measles outbreaks, hospitals looked to the Rx3000 for its UV light technology, which has been proven as an effective hospital infection control technology, as seen in the attached news clip: https://abcnews.go.com/WNT/video/measles-outb...on=4765066
More information on Rx3000 and consumer RxAir UV Light Air Purifiers is available at http://www.RxAir.com, 1 866.674.5238, jrotman@vytex.com
About RxAir
RxAir promotes a healthy lifestyle through the use of its innovative, patented ViraTech air purification technology, thereby improving the quality of life of each and every customer. Independently tested by EPA- and FDA-certified laboratories, the RxAir has been proven to destroy greater than 99% of bacteria and viruses and reduce concentrations of odors and VOCs. The RxAir uses high-intensity germicidal UV lamps that destroy bacteria and viruses instead of just trapping them, setting it apart from ordinary air filtration units. RxAir® and ViraTech ® are registered trademarks of UV Flu Technologies, Inc. For more information, visit http://www.RxAir.com
About Vystar Corporation:
Based in Worcester, Mass., Vystar® Corp. (OTC Pink: VYST) is the exclusive creator of Vytex Natural Rubber Latex (NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products, and the owner of RxAir UV light air purification products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products bringing Vytex NRL to market in adhesives, gloves, balloons, condoms, other medical devices and natural rubber latex foam mattresses, toppers, and pillows. For more information, visit www.vytex.com.
Contacts:
Media: Julie Shepherd, Accentuate PR, 847 275 3643, Julie@accentuatepr.com
Investors: Steven Rotman, Vystar CEO, 508-791-9114, srotman@vytex.com
Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"
. Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...bb926a9a6c
1
